期刊文献+

糖尿病流行现状及防治对策 被引量:71

The prevalence actuality and the countermeasure of prevention and cure of diabetes mellitus
暂未订购
导出
摘要 目前全球已确诊糖尿病 (DM) 1.35亿人 ,预测 2 0 2 5年增至 2 .99亿。我国糖尿病患者约 30 0 0万人 ,成人患病率达 3.2 1%。40岁以上 DM为 7.1% ,糖耐量减低 (IGT)为 8.4% ,并逐渐增多 ,防治 DM已刻不容缓。本文介绍 WHO与美国糖尿病协会 (ADA )审议通过的 DM诊断标准与分型和国际糖尿病联盟 (IDF)提出的糖尿病防治对策、糖尿病现代综合治疗原则 ,以及近年治疗方法药物研究进展及前景。 In the 21th century,the prevalence of diabetes would be increasing rapidly all over the world.At present there are 135 million diabetic patients in the world and it is predicted that the diabetes will increase to 299 million in 2025. Diabetic patients in China are 30 million in number and the prevalence of diabetes in adults is 3.21%. Prevalence is 7.1% in populations over 40 years of age and the prevalence of IGT is 8.4%. The prevalence of diabetes is rising and a concerted effort must urgently be made to control and to prevent the disease. In this article, we introduced the standard of diagnosis and classification of diabetes adopted by WHO and ADA, the principle of integrated treatment was put forward by IDF,as well as the development and prospect of the treatment and the research of medicine for diabetes in recent years.
作者 杨明功
出处 《疾病控制杂志》 2000年第3期193-196,共4页 Chinese Journal of Disease Control and Prevention
关键词 糖尿病 诊断 治疗 预防 控制 diabetes mellitus diagnosis treatment prevention and control
  • 相关文献

参考文献11

  • 1李秀钧 刘国良.第16届国际糖尿病联盟会议纪要[J].实用糖尿病杂志,1997,3(5):2-2.
  • 2杨明功.提高对糖尿病的认识 [J].基层实用医学,2000,5(2):69-69.
  • 3 American Diabetes Association. Report of the Expert Committee on the diagnosis and classifacation of Diabetes Mellitus [J]. Diabetes Care, 1997,20:1183.
  • 4钱荣立.胰岛素抵抗:2型糖尿病的基本诱因[J].中国糖尿病杂志,2000,8(1):62-64. 被引量:33
  • 5李光伟.应切实加强对葡萄糖耐量低减人群的管理[J].中华内分泌代谢杂志,1999,15(1):1-2. 被引量:58
  • 6 DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in IDDM [J]. N Engl J Med, 1993,329:977.
  • 7李秀钧 齐今吾.UKPDS简介与评价[J].实用糖尿病杂志,1999,(3):2-2.
  • 8陈亮,杨华章.糖尿病口服药物治疗进展[J].国外医学(内分泌学分册),2000,20(3):140-143. 被引量:26
  • 9  Mark NF, Angelyn MB. Oral angent therapy in the treatment of type 2 diabetes [J]. Diabetes Care, 1999,22(suppl 3):C61~64.
  • 10 James K, Sowers MD, Melvin A, et al. Diabetes and cardiovascular disease [J]. Diabetes Care, 1999,22(suppl 3):C14.

二级参考文献22

  • 1潘长玉 陆菊平 等.首都钢铁公司成年人群糖尿病患病率调查[J].中华医学杂志,1995,75:409-411.
  • 2向红丁,中国糖尿病杂志,1998年,6卷,131页
  • 3Pan X R,Diabetes Care,1997年,20卷,537页
  • 4团体著者,中华内科杂志,1997年,36卷,384页
  • 5潘长玉,中华医学杂志,1995年,75卷,409页
  • 6Owens DR.Repaglinide-prandialglucose regulator:a new class of oral antidiabetic drugs 〔J〕.Diabet Med,1998,15(Supp14):S28~S36.
  • 7John R.White Jr,Pharm D.The Pharmacological reduction of blood glucose in patientswith type 2 diabetes mellitus 〔J〕.Clin Diabet,1998,16:2~4.
  • 8BalfourJA,FauldsD.Repaglinide〔J〕.DrugsAging,1998,13:173-180.
  • 9Lefebvre PJ,Scheen AJ.The postprandial state risk of cardiovascular disease 〔J〕.DiabetMed,1998,15(Supp1 4):S63~S68.
  • 10Hatorp V,Huang WC,Strange P.Pharmacokinetic profiles of repaglinide in elderlysubjects with type 2 diabetes 〔J〕.J Clin Endocrinol Metab,1999,84:1475~1478.

共引文献130

同被引文献408

引证文献71

二级引证文献492

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部